Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abnormal, abstract, answer, answered, Atara, azacitidine, behalf, biliary, bilirubin, bone, bore, causality, Chancery, characteristic, checkpoint, chemotheraphy, chemotherapy, cholangiocarcinoma, chondrosarcoma, cohort, constipation, counterclaimed, CR, CRh, CRi, cutoff, DGCL, differentiation, director, doctrine, doublet, fatal, fiduciary, forgoing, forum, fostmatinib, glioma, HCST, hematopoietic, hepatic, inapplicable, incomplete, intrahepatic, laboratory, linked, liver, markup, marrow, metabolism, monotherapy, morphologic, neutrophil, Nordisk, Novo, numerically, OIG, Op, ORR, OS, pembrolizumab, peripheral, QTc, RBC, remission, rentable, requestor, subsidiary, sum, survival, transplant, understood, unrestricted, upcoming, wholly, writing
Removed:
drawn, mark, NaN, NSCLC, ratably
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view